Smell Training and Trigeminal Nerve Stimulation for COVID-related Smell Loss
Smell Dysfunction, Olfactory Disorder, Long COVID
About this trial
This is an interventional treatment trial for Smell Dysfunction focused on measuring COVID-19, Parosmia, Hyposmia, Anosmia, Phantosmia, Dysosmia, Olfactory Training, Neuromodulation, Non-invasive Brain Stimulation
Eligibility Criteria
Inclusion Criteria: treatment-seeking for COVID-related persistent SL (anosmia, hyposmia, phantosmia or parosmia) SARS-coV-2 PCR-positive test prior to April 2021 normal sense of smell prior to COVID naïve to both smell training (ST) and trigeminal nerve stimulation (TNS) able to comprehend English and provide informed consent Exclusion Criteria: history of head injury (e.g. sport, accident, combat blast) sinonasal condition (e.g. upper respiratory infection, rhinosinusitis, polyps) neurological disorder (e.g. epilepsy, neurodegenerative disorder, narcolepsy) serious mental illness (e.g. schizophrenia, bipolar, or other psychotic disorder) suicidal ideation within the last month current (≤6 months) heavy cigarette smoker (heavy defined as ≥ 10 pack-years) oral/nasal steroids or other intranasal medications within the last month immunomodulatory medications pregnant or trying to become pregnant
Sites / Locations
- Medical University of South CarolinaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Combination Trigeminal Nerve Stimulation (TNS) and active Smell Training (ST)
Active Smell Training (ST)
Placebo Smell Training (PBO)
30 minutes of once/day TNS and twice/day ST conducted 5 days/week for 12 weeks and a total of 60 stimulation and 120 smell training sessions
5 minutes of daily ST conducted twice/day, 5 days/week for 12 weeks and a total of 120 training session
5 minutes of daily PBO conducted twice/day, 5 days/week for 12 weeks and a total of 120 training sessions